Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 09, 2006. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of GBP 14.976 per Ordinary Share.
Material Changes
The filing details an increase in shareholdings for five individuals following the re-investment of dividends paid on January 05, 2006. The specific increases are:
- Mr R Bondy: 160 shares
- Mr J Heslop: 108 shares
- Mrs C Witty: 215 shares
- Mrs C Pulman: 11 shares
- Dr D Pulman: 57 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is strictly a regulatory disclosure of director share transactions in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Investor Verification Points
- Verify the total number of shares held by the named individuals post-transaction to assess their total exposure.
- Confirm the dividend reinvestment plan terms applicable to the January 05, 2006 payment.
- Check subsequent filings for any further changes in director holdings or related party transactions.